enow.com Web Search

  1. Ads

    related to: zoetis order cytopoint form 1

Search results

  1. Results from the WOW.Com Content Network
  2. Lokivetmab - Wikipedia

    en.wikipedia.org/wiki/Lokivetmab

    Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. [1] It acts against interleukin 31 (IL-31), [2] which is a cytokine involved in causing itchiness (pruritus). [2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks. [3]

  3. Zoetis - Wikipedia

    en.wikipedia.org/wiki/Zoetis

    Zoetis Inc. (/zō-EH-tis/ [4]) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. [ 5 ] [ 4 ] [ 6 ] The company was a subsidiary of Pfizer , [ 7 ] the world's largest drug maker , but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company.

  4. Zoetis (ZTS) Q3 2024 Earnings Call Transcript - AOL

    www.aol.com/zoetis-zts-q3-2024-earnings...

    Zoetis (NYSE: ZTS) Q3 2024 Earnings Call ... first-line treatment like Cytopoint, the first monoclonal antibody to treat itch, and applicable chew a convenient chewable that enhances compliance ...

  5. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab.

  6. Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store? - AOL

    www.aol.com/news/zoetis-zts-report-q3-earnings...

    Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.

  7. Zoetis' (ZTS) Q1 Earnings Beat Estimates, Revenues In Line - AOL

    www.aol.com/news/zoetis-zts-q1-earnings-beat...

    Zoetis (ZTS) beats on earnings in the first quarter of 2020 while sales meet estimates. Domestic revenues bumped up owing to growth in new parasiticide products and a robust dermatology portfolio.

  1. Ads

    related to: zoetis order cytopoint form 1